Skip to main content
SleepCited

CBD 不眠症

A

合計1,152名の参加者を対象とした9件の研究(メタアナリシス1件、RCT 3件を含む)に基づく。研究間で結果にばらつきが見られる。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dcbd\u0026condition\u003Dinsomnia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

The evidence for CBD as a standalone remedy for insomnia is mixed — some studies show benefits while others do not, so more research is needed before it can be confidently recommended.

  • Results are mixed across 9 studies, even at Grade A evidence level due to study volume
  • A 2025 meta-analysis found inconsistent effects of cannabinoids on sleep quality
  • Some studies used medicinal cannabis blends rather than pure CBD, complicating comparisons
  • Individual responses to CBD for sleep may vary significantly

Key Study Findings

Review
Therapeutic Use of Cannabis and Cannabinoids: A Review.
Dose: None vs: None Outcome: None 効果: SMD=-0.29 (nausea/vomiting); SMD=0.57 (body weight in HIV/AIDS) None

対象集団: adults using cannabis or cannabinoids for medical purposes

Randomized Controlled Trial n=20 Double-blind
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised …
Dose: 10 mg THC and 200 mg CBD vs: Placebo Outcome: Total sleep time and REM sleep parameters 効果: -24.5 min TST; -33.9 min REM sleep p=0.05 (TST); p<0.001 (REM)

対象集団: Patients with DSM-5 insomnia disorder (16F, mean age 46.1)

Observational Study n=3118
Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study.
Dose: None vs: None Outcome: Sleep disturbance signals for ASMs in FAERS 効果: 1570 insomnia reports (most frequent) None

対象集団: Epilepsy patients on ASMs (FAERS Q1 2004-Q2 2025)

Cohort Study n=155 52 weeks Open-label
Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis.
Dose: Median 15mg THC + 15mg CBD daily vs: Opioids only (separate cohort) Outcome: Opioid consumption reduction at 12 months 効果: Median 2.7 vs 42.3 mg/day <0.05 (ITT)

対象集団: Chronic non-cancer pain patients on opioids

Other n=27 56 weeks Open-label
Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett …
Dose: 5-20 mg/kg/day vs: None (single-arm) Outcome: Seizure frequency reduction 効果: 66.6% had seizure reduction, 25.9% >75% None

対象集団: Rett Syndrome and CDKL5 patients with drug-resistant epilepsy

Randomized Controlled Trial n=30 2 weeks Double-blind
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary …
Dose: 150 mg CBD daily vs: Placebo Outcome: Daytime neurocognitive performance 効果: None >0.05

対象集団: Adults with primary insomnia

Key Statistics

103

研究数

41554

参加者数

Mixed

A

グレード

Referenced Papers

Clinical psychology review 2025 5 件の引用
Clinical breast cancer 2025 1 件の引用
Psychopharmacology bulletin 2025 1 件の引用
Current psychiatry reports 2024 8 件の引用
Cannabis and cannabinoid … 2023 28 件の引用
Psychiatry research 2022 43 件の引用
Journal of primary … 2022 28 件の引用
Journal of medical … 2021 21 件の引用
Current opinion in … 2021 15 件の引用
Journal of cannabis … 2020 77 件の引用
Internal medicine journal 2020 18 件の引用
Schmerz (Berlin, Germany) 2020 8 件の引用
Journal of AOAC … 2019 96 件の引用
Current treatment options … 2019 20 件の引用
Journal of psychosocial … 2019 3 件の引用
The Medical letter … 2019
Current psychiatry reports 2017 394 件の引用
Cannabis and cannabinoid … 2016 77 件の引用
International journal of … 2016 16 件の引用
British journal of … 2013 14 件の引用
Pharmaceuticals (Basel, Switzerland) 2012 194 件の引用
Occupational medicine (Oxford, … 2012 33 件の引用
The Urologic clinics … 2002 20 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

sleep:
25-150 mg, 1 hour before bed

上限量: Not established; FDA max studied ~20 mg/kg/day

研究で検討された用量

用量 期間 効果 N
None -- Mixed --
10 mg THC and 200 mg CBD -- Negative 20
None -- Mixed 3118
Median 15mg THC + 15mg CBD daily 52 weeks Positive 155
5-20 mg/kg/day 56 weeks Positive 27
150 mg CBD daily 2 weeks Neutral 30
10 mg/kg/day CBD oral during pregnancy -- Negative --
None -- Positive 141

推奨摂取タイミング: 1 hour before bed

Safety & Side Effects

報告されている副作用

  • Fatigue
  • Diarrhea
  • Changes in appetite
  • Dry mouth
  • Liver enzyme elevation at high doses

既知の相互作用

  • CYP3A4/CYP2C19 substrates — CBD inhibits these liver enzymes
  • Blood thinners (warfarin) — CBD may increase warfarin levels
  • Clobazam — CBD significantly increases clobazam levels
  • Sedatives — additive drowsiness

耐容上限摂取量: Not established; FDA max studied ~20 mg/kg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does CBD help with 不眠症?
Based on 103 studies with 41,554 participants, there is strong evidence from multiple clinical trials that CBD may support 不眠症 management. Our evidence grade is A (Strong Evidence).
How much CBD should I take for 不眠症?
Studies have used various dosages. A commonly studied range is 25-150 mg, 1 hour before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of CBD?
Reported side effects may include Fatigue, Diarrhea, Changes in appetite, Dry mouth. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for CBD and 不眠症?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 103 peer-reviewed studies with 41,554 total participants. The overall direction of effect is mixed.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。